Power vision accommodating iol
If you are considering RLE, you must be willing to accept these risks, which can occur even when RLE is performed flawlessly by a skilled and experienced refractive surgeon or cataract surgeon.
RLE risks and potential complications include: Many refractive surgeons feel the best candidates for RLE are people with moderate to high hyperopia (farsightedness) and people with hyperopia who also are over age 45 and have presbyopia.
Belmont, California-based Power Vision offers an implant with a different mechanism.
It has developed an accommodating IOL (AIOL), which contains a tiny amount of fluid that moves in response to the natural muscle forces in the eye.
is working on represents a potential game-changer in the category with the promise to offer patients a natural, continuous range of near to far vision.” Alcon's investment amount in Power Vision was undisclosed, but the companies said the fund will be used for further device development and future clinical trials, as well as provide Alcon the option to purchase Power Vision in the future.
“We are excited about our new alliance with Alcon, and look forward to working together to bring this exciting technology to market,” said Barry Cheskin, president, CEO, and co-founder of Power Vision.
In 2014, Novartis announced a partnership with Google to create a smart lens to correct presbyopia and measure glucose levels in tears of diabetics.
RLE can correct a wide range of refractive error, from 8.00 diopters (D) of farsightedness to -20.0 D of nearsightedness.
Refractive lens exchange (RLE) is a type of vision correction surgery in which the eye's natural lens is removed and replaced with a man-made intraocular lens (IOL).
Alternative names occasionally used for RLE are clear lens exchange, clear lens extraction or CLE. Refractive lens exchange is essentially the same surgical procedure as cataract surgery, which is performed on approximately three million Americans each year.
Alcon, which represents 20 percent of Novartis’ revenue, dropped 13 percent in the fourth quarter of 2015.
Novartis CEO Joe Jimenez has said a failure to innovate was to blame for Alcon's underperformance.